Introduction
Cerebral venous thrombosis (CVT) is an increasingly recognized neurological emergency. Intracranial hemorrhages (ICH) as hemorrhagic infarctions or subarachnoid hemorrhage (SAH) complicate nearly 40% of CVT cases [1] . Treatment of CVT with anticoagulation (AC) is recommended, though the evidence for its benefit is not substantial [2] . Though AC for CVT continues to be beneficial even in the presence of ICH [1, 3, 4] , the optimum time to start such a treatment option has not been clearly defined. We report a case of CVT with SAH, who responded favorably to AC.
Case Report
A 38-year-old woman presented with acute onset of severe diffuse headache with vomiting for the last 12 h. She was not pregnant or puerperal, nor on contraceptive pills, and did not have any past or family history of venous thrombosis. She was fully con-
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Discussion
CVT is an uncommon serious neurological emergency that is being increasingly diagnosed due to better clinical awareness and improved imaging techniques. Prothrombotic risk factors, infections and Behcet's disease are among the most frequently identified causes [2] . Presenting symptoms and signs include headache, epilepsy, focal neurological deficits and impairment of consciousness [2] . The priority of treatment in the acute stage should be to stabilize the patient's condition and to prevent or reverse cerebral herniation [2] .
Although there is no substantial evidence-based consensus that AC is beneficial in CVT, most neurologists currently start treatment with heparin as soon as the diagnosis is confirmed, even in the presence of hemorrhagic complications [2] . Heparin treatment has been shown to be beneficial rather than hazardous when CVT is associated with ICH [1, 3, 4] . Of 43 patients with CVT and ICH, Einhäupl et al. [1] reported a mortality of 15% in heparin-treated patients compared to 69% that in those who did not receive heparin. Of 29 patients with ICH and CVT who were treated with low-molecular-weight heparin, de Bruijn and Stam [3] reported 6 deaths, but none of them could be attributed to new or enlarged cerebral hemorrhage. In our case, AC therapy was associated with a favorable outcome, bearing in mind it was started 4 days after the onset of symptoms and after confirming that SAH had regressed. An important point is the safety of immediate AC with cases of SAH and CVT upon presentation. This point needs further clarification as in most of the reported cases of CVT with ICH, heparin treatment was delayed [1, 3, 6, 7] . Wingerchuk et al. [6] stated that AC was safely initiated within several days in clinically stable patients with non-temporal-lobe hemorrhagic infarcts of unchanging volume, and highlighted that the location and unchanged volume on serial CT may be important factors influencing the safety of AC therapy in patients with CVT and hemorrhagic infarcts. Oppenheim et al. [7] suggested performing magnetic resonance angiography, or preferably digital subtraction angiography, to rule out intracranial aneurysm before AC in cases of CVT with SAH. In the study by Einhäupl et al. [1] , mean delay between the onset of symptoms and heparin treatment was 33 days; in the study of Bruijn and Stam [3] , this was 10.6 days. No studies were found to evaluate the time interval when enlargement of venous intracerebral hemorrhages is more likely to occur; however, in general, active bleeding into the brain is usually confined to the first 6 h following ICH, with 10-15% of patients showing hematoma enlargement between 6 and 24 h from the onset of spontaneous ICH [8] .
Conclusion
AC treatment for cases of CVT with hemorrhagic complications was not associated with adverse outcome. However, if ICH is present, immediate AC for CVT at presentation and within 24 h from onset of symptoms cannot be safely recommended, as in almost all previous reports there was a delay in the onset of AC ranging between 4 and 33 days. Although there is no known definite waiting period, repeating CT after at least 1 day from onset of symptoms to confirm that ICH is regressing or at least not progressing may be advisable before starting AC. It may also be prudent to perform magnetic resonance angiography or digital subtraction angiography before AC in cases of CVT with SAH to rule out a coincident intracranial aneurysm.
